Johnson & Johnson (JNJ): A Dividend King Built for Uncertain Markets
Johnson & Johnson (JNJ) offers something that’s particularly valuable when the economic outlook becomes less certain: a business built around products people continue to need regardless of what the economy is doing. Combine that defensive quality with 64 consecutive years of dividend increases, and J&J remains one of our favorite blue-chip stocks for long-term income investors.
Healthcare tends to hold up relatively well during economic downturns because demand for medicine, surgery and other essential treatments doesn’t simply disappear in a recession. Johnson & Johnson pairs that resilience with a remarkably consistent record of returning cash to shareholders. Its 64-year streak of annual dividend increases easily qualifies it as a Dividend King.
But we don’t view J&J simply as a defensive income stock. The company has been shedding slower-growing businesses and directing more of its attention toward faster-growing areas of healthcare, including hematology. That focus should help support the revenue and earnings growth needed to continue raising the dividend while also creating opportunities for long-term share-price appreciation.
The numbers behind the dividend are reassuring. Johnson & Johnson is expected to earn $11.08 per share in 2026, compared with forward annual dividends of $5.36 per share. That puts its forward payout ratio below 50%, leaving a considerable portion of earnings available for reinvestment and other corporate priorities.
Investors currently get a forward dividend yield of about 2.1%, with the payout growing at a mid-single-digit annual rate. That’s not an unusually high yield, but we think the combination of current income, consistent dividend growth and the company’s defensive characteristics is more important. After 64 straight annual increases, J&J has demonstrated its commitment to shareholders through many different economic cycles.
The stock trades around $256 per share and at roughly 21 times forward earnings. Its market capitalization stands at approximately $617 billion.
For investors looking for explosive growth, Johnson & Johnson probably isn’t the first stock that comes to mind. That’s not why we’re interested in it. The appeal here is the combination of a recession-resistant healthcare business, a sustainable payout, continued operational growth and one of the longest dividend-growth records on the market.
That makes Johnson & Johnson a stock we think investors can comfortably hold through both good markets and bad, collecting a growing stream of income while giving the business time to compound over the long run.
